<DOC>
	<DOC>NCT00966251</DOC>
	<brief_summary>The objective of this pilot study is to evaluate the safety, tolerability and activity of the monoclonal antibody CT-011 administered intravenously to patients with Primary Hepatocellular Carcinoma.</brief_summary>
	<brief_title>Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>1. Subjects aged 18 years and above, both genders. 2. Histologically or cytologically confirmed Primary Hepatocellular Carcinoma (HCC) 3. No fibrolamellar subtype HCC 4. Not eligible for any other systemic antineoplastic treatment approved for HCC 5. Not eligible for Transarterial chemoembolization (TACE ). 6. No more than 1 prior systemic therapy. Previous TACE or Radiofrequency ablation (RFA) that were used for HCC, are permitted. 7. Not a candidate for curative surgical resection or liver transplantation 8. Measurable disease defined by the identification at least 1 measurable lesion by MRI using RECIST criteria. Tumor in area of TACE or RFA must be enlarging postprocedure to be considered measurable disease. 9. Alphafetoprotein (AFP) greater than the upper limit of normal (ULN) 10. Child's Pugh classification A 11. ECOG performance status 01 1. Patients progressing to liver failure. 2. No core biopsy within the past 7 days 3. Patients who are eligible for Transarterial Chemoembolization (TACE) 4. Patients on concurrent antineoplastic therapy (including interferon) 5. Patients who have received any systemic antineoplastic therapy not approved for the treatment of HCC. 6. Patients on concurrent steroids, other than those allowed for routine antiemetics, or inhaled steroids 7. Presence of metastasis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Primary Hepatocellular Carcinoma</keyword>
</DOC>